Legend Biotech Corporation Sponsored ADR LEGN
- Market cap
- $3.7B
- P/E
- 0.0×
Follow LEGN
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | 24.64 | 23.41 | 30.76 | 42.91 | 32.08 | 21.19 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | 43.24 | 58.00 | 57.67 | 77.32 | 70.13 | 45.30 |
High Price
|
|||
| — | — | — | 650 | 882 | 1,071 | 1,390 | 1,800 | 2,609 | 2,965 |
Employees
|
|||
| — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | 24 | 63 | 64 | 82 | 69 | 117 | 285 | 627 | 1,029 |
Revenue
|
|||
| — | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 44.14% | 49.42% | 62.60% | 60.34% |
Gross Margin
|
|||
| — | 14 | (2) | (130) | (308) | (407) | (446) | (520) | (158) | (283) |
EBT
|
|||
| — | 58.65% | (2.56%) | (202.47%) | (376.09%) | (591.63%) | (380.94%) | (182.41%) | (25.20%) | (27.47%) |
EBT Margin
|
|||
| — | 0 | (2) | (130) | (308) | (407) | (446) | (520) | (158) | (283) |
Net Income
|
|||
| — | 0 | 2 | 5 | 10 | 14 | 18 | 20 | 21 | 29 |
Depreciation
|
|||
| — | 0.15 | 0.63 | 0.64 | 0.69 | 0.49 | 0.74 | 1.62 | 3.43 | 5.58 |
Revenue/Sh
|
|||
| — | 0.04 | (0.03) | (1.33) | (2.57) | (2.87) | (2.81) | (2.94) | (0.97) | (1.61) |
Earnings/Sh
|
|||
| — | (0.02) | 3.08 | (0.83) | (1.89) | (1.41) | (1.27) | (2.23) | (0.79) | (0.54) |
Cash Flow/Sh
|
|||
| — | 0.00 | (0.21) | (0.39) | (0.42) | (0.32) | (0.14) | (0.13) | (0.08) | (0.16) |
Capex/Sh
|
|||
| — | (0.02) | 2.87 | (1.22) | (2.31) | (1.73) | (1.41) | (2.36) | (0.86) | (0.70) |
Free CF/Sh
|
|||
| — | 0.08 | 0.09 | (1.23) | 2.37 | 5.44 | 4.68 | 7.11 | 5.69 | 5.44 |
Book Value/Sh
|
|||
| — | 157 | 100 | 100 | 118 | 141 | 159 | 176 | 183 | 184 |
Shares
|
|||
| — | 1.43 | 3.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | 0.00 | 0.00 | 56.44 | 40.68 | 95.39 | 81.88 | 46.04 | 11.08 | 3.89 |
PS Ratio
|
|||
| — | 0.00 | 0.00 | 0.00 | 11.87 | 8.57 | 10.59 | 8.57 | 5.72 | 4.00 |
PB Ratio
|
|||
| — | 0.00 | 0.00 | 55.04 | 34.53 | 84.31 | 73.94 | 41.64 | 9.56 | 3.45 |
EV/Sales
|
|||
| — | 0.00 | 0.00 | (16.48) | (8.25) | (17.76) | (15.17) | (13.39) | (32.34) | (27.43) |
EV/FCF
|
|||
| — | (2) | 308 | (83) | (223) | (198) | (201) | (393) | (144) | (100) |
Op' Cash Flow
|
|||
| — | (1) | (21) | (39) | (50) | (45) | (22) | (23) | (14) | (29) |
Capex
|
|||
| — | (2) | 287 | (122) | (273) | (244) | (224) | (416) | (158) | (129) |
FCF
|
|||
| — | 179 | 168 | 79 | 432 | 721 | 801 | 1,281 | 1,006 | 611 |
Working Cap'
|
|||
| — | 0 | 5 | 6 | 4 | 121 | 265 | 281 | 301 | 319 |
Total Debt
|
|||
| — | (2) | (211) | (153) | (502) | (762) | (762) | (1,028) | (821) | (629) |
Net Debt
|
|||
| — | 12 | 9 | (123) | 280 | 766 | 744 | 1,251 | 1,041 | 1,002 |
Sh' Equity
|
|||
| — | 2.80% | (1.30%) | (37.10%) | (60.17%) | (43.86%) | (36.43%) | (32.60%) | (10.06%) | (17.44%) |
ROA
|
|||
| — | 0.00% | 0.00% | 0.00% | 0.00% | (7,010.37%) | 0.00% | (115.31%) | (56.37%) | (50.54%) |
ROIC
|
|||
| — | 89.19% | (26.96%) | 232.83% | (385.65%) | (77.15%) | (59.11%) | (51.94%) | (15.45%) | (29.06%) |
ROE
|
|||
Legend Biotech Corporation Sponsored ADR peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| XENE Xenon Pharmaceuticals Inc. | $3.7B | 0.0× | Compare |
| ACAD ACADIA Pharmaceuticals Inc. | $3.8B | 9.2× | Compare |
| IDYA IDEAYA Biosciences, Inc. | $3.6B | 0.0× | Compare |
| TARS Tarsus Pharmaceuticals, Inc. | $3.6B | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| TLX Telix Pharmaceuticals Limited | $3.9B | — | Compare |
| CELC Celcuity, Inc. | $3.9B | 0.0× | Compare |
| RLAY Relay Therapeutics, Inc. | $3.9B | 0.0× | Compare |
| ARQT Arcutis Biotherapeutics, Inc. | $3.4B | 122× | Compare |
Legend Biotech Corporation Sponsored ADR (LEGN) key facts
- Legend Biotech Corporation Sponsored ADR (LEGN) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
- Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024.
- As of September 25, 2026, LEGN traded at $19.11, a market capitalization of $3.7 billion.
- Return on equity was −29.1% and debt-to-equity 0.13.
Legend Biotech Corporation Sponsored ADR (LEGN) Latest News
25 Sep
Five-year follow-up from CARTITUDE-2 Cohort A (n=20) shows that five years after a single CARVYKTI infusion, 50% remain alive and progression-free off therapy. Median PFS is 60.5 months; five-year overall survival is 69.2% with OS not reached. Median follow-up is 60.7 months, and 10 of 20 patients meet the ≥5-year progression-free criterion. Safety through extended follow-up aligns with the known CARVYKTI profile, with no new CAR-T–related neurotoxicity observed. Since prior analysis, one patient developed acute myeloid leukemia and two deaths occurred due to progressive disease or a new cancer. The data support the potential of earlier CARVYKTI use to achieve durable, treatment-free remission in relapsed/refractory multiple myeloma." Long-term survival signals for cilta-cel in earlier-line RRMM could meaningfully boost investor sentiment and future sales, though the data come from a small cohort.
Legend Biotech has appointed Ingrid Zhang as CEO to accelerate global adoption of CARVYKTI and convert clinical leadership into a durable cash-generating franchise. The company holds about $965 million in cash and equivalents after a $212 million net equity raise to fund CAR-T manufacturing and expansion. In Q2 2026, CARVYKTI net trade sales rose 50% YoY to roughly $657 million, with ex-US revenue up 128% as the product reached 348 treatment sites across 19 markets, including Ireland. LB2501 showed strong signals (100% ORR, 83.3% CRR at higher doses in relapsed/refractory B-cell NHL); LB2102 posted 28.6% ORR in small-cell lung cancer. Costs are rising with growth; income tax expense jumped to $22.3 million amid an ongoing Chinese pricing negotiation, potentially altering the tax obligation. Short interest remains elevated; the stock trades at a forward P/E around 27.6, implying upside if manufacturing scales. CEO appointment and stronger CARVYKTI adoption plus solid liquidity position create meaningful upside opportunity, tempered by manufacturing constraints and tax uncertainties.
15 Sep
Legend Biotech appoints new CEO from Novartis, fueling buyout speculation for LEGN. New CEO hire from Novartis directly triggers buyout speculation that can shift company trajectory and investor sentiment.
Legend Biotech appoints Ingrid Zhang as Chief Executive Officer. CEO change may influence company strategy and operations but effects remain limited without further details.
Legend Biotech names Novartis executive as CEO. New CEO hire from Novartis may moderately shift Legend Biotech strategy and operations.
10 Sep
Legend Biotech will present updated long-term and real-world evidence from its CARVYKTI clinical program at the International Myeloma Society Annual Meeting. CARVYKTI clinical data update at medical meeting can moderately affect Legend Biotech competitive positioning and investor sentiment.
11 Aug
Legend Biotech (LEGN) released its Q2 2026 earnings call transcript covering financial results, operational updates and forward outlook. Earnings call transcript discloses key financial metrics and strategy that can materially shift investor sentiment and stock trajectory.
Legend Biotech achieved its first profitable quarter in Q2 2026, driven by core product performance as detailed in earnings call highlights. First profitable quarter represents major financial milestone that can significantly lift investor sentiment and valuation.
Legend Biotech reports second quarter 2026 financial results and recent business highlights. Quarterly results and highlights disclose financial metrics and pipeline updates that drive stock valuation and investor outlook.
Legend Biotech shares rose 5% after Q2 earnings and revenue both exceeded analyst estimates. Q2 beat produced a 5% share price rise reflecting moderate but typical quarterly impact on near-term sentiment.
Legend Biotech Q2 earnings call highlighted financial results, operational updates and forward outlook for the company. Earnings call details on results and outlook may moderately shift near-term investor sentiment and valuation.
29 Jul
Legend Biotech CEO exits, testing management stability around its CAR-T multiple myeloma strategy. CEO departure introduces leadership uncertainty that could shift execution of core CAR-T strategy.
Legend Biotech CEO resigns, which may render LEGN stock undervalued. CEO departure creates leadership uncertainty that can sway short-term strategy and investor views on LEGN.
Legend Biotech replaces CEO Ying Huang with interim chief Alan Bash. CEO change to interim status signals leadership transition that can alter strategy and investor sentiment.
27 Jul
Legend Biotech stock drops 15% after sudden CEO exit, though an analyst maintains optimism regarding the company's under-development lymphoma asset. Sudden CEO exit drives 15% stock plunge and directly affects near-term investor sentiment and leadership stability.
FDA scientists question Capricor data. Legend Biotech CEO steps down. CEO departure signals major leadership shift likely to influence strategy and investor views on LEGN.
Legend Biotech Corporation Sponsored ADR (LEGN) announces CEO transition. CEO transition introduces moderate uncertainty around future strategy and leadership execution.
25 Jun
Legend Biotech price target raised to $49 citing progress in LB5006 clinical trials. Price target lift to $49 on LB5006 advances indicates meaningful pipeline momentum that can lift LEGN valuation and sentiment.
22 Jun
Legend Biotech reports complete response in five of six patients at highest dose. Positive high-dose efficacy data in early trials signals major upside for drug development trajectory and investor sentiment.
17 Jun
Legend Biotech Corporation announces proposed public offering of shares. Proposed public offering signals major capital raise with likely share dilution and direct pressure on stock price and investor sentiment.
Legend Biotech Corporation prices its public offering of common stock to raise capital from investors. Public offering raises operating capital but dilutes existing shareholders and pressures near-term share price.
15 Jun
Legend Biotech establishes clinical proof-of-concept for LB2501, a potential first-in-class in vivo CD19/CD20 dual-targeting CAR-T, in relapsed/refractory B-cell non-Hodgkin lymphoma. Clinical proof-of-concept for novel CAR-T candidate advances Legend Biotech pipeline and strengthens competitive positioning in oncology.
14 Jun
Legend Biotech establishes clinical proof-of-concept for LB2501, its potential first-in-class in vivo CD19/CD20 dual-targeting CAR-T, in relapsed/refractory B-cell non-Hodgkin lymphoma. Positive clinical proof-of-concept data on novel LB2501 CAR-T advances Legend Biotech pipeline and bolsters long-term growth prospects.
4 Jun
Legend Biotech shares rose 26.2% after early clinical data showed success for its in vivo CAR-T therapy in B-cell lymphoma patients. Early positive in vivo CAR-T data in lymphoma marks major pipeline progress that can materially shift Legend Biotech's competitive position and investor outlook.
3 Jun
Legend Biotech shares surge on promising early clinical data for its in vivo cell therapy targeting lymphoma. Early positive data on new in vivo lymphoma therapy signals major pipeline advance likely to lift stock and long-term prospects.
2 Jun
Legend Biotech (LEGN) stock surges 42% after reporting promising results for its cancer therapy. Positive cancer therapy data triggers 42% share price jump and signals major pipeline progress.
Legend Biotech's cancer treatment achieves 100% success rate. 100% success rate for core cancer therapy signals major positive shift in LEGN clinical and market trajectory.
Legend Biotech's LB2102 delivers mixed small cell lung cancer results at ASCO 2026 while Novartis accelerates manufacturing. Mixed LB2102 trial data creates moderate effects on Legend pipeline perception and near-term sentiment.
Legend Biotech will present initial Phase 1 in vivo CAR-T data for LB2501 in NHL as a late-breaking oral at EHA 2026. Early Phase 1 data presentation for novel in vivo CAR-T candidate can moderately affect near-term sentiment and pipeline perception but remains too preliminary for major trajectory shift.
1 Jun
Legend Biotech CARVYKTI data and adoption trends are positioned against the company's depressed share price. CARVYKTI data and adoption trends may moderately affect LEGN financial performance and investor sentiment.